Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
Lilly Drug Wins Narrow FDA Advisory Committee Backing
Lilly surmounted the ODAC hurdle, but more obstacles may lay ahead for Cyramza in first-line lung cancer • Source: Shutterstock 
